OSE Immunotherapeutics Welcomes Thomas Gidoin as CFO

OSE Immunotherapeutics Welcomes Thomas Gidoin as CFO

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) proudly announces the appointment of Thomas Gidoin as its new Chief Financial Officer. Thomas brings with him over 15 years of extensive experience in capital markets, financial strategies, and corporate governance, making him a valuable addition to the Executive Committee.

Thomas Gidoin's Extensive Background

Thomas Gidoin is not a stranger to the biopharmaceutical arena. With a proven track record in both private and public sectors, he has excelled in strategic financial leadership roles. Prior to joining OSE Immunotherapeutics, Thomas served as the Chief Financial Officer at Advesya, a private biotech company focused on oncology and autoimmune diseases. His tenure there was preceded by an impactful eight years at GenSight Biologics, a publicly traded company that specializes in gene therapies for neurodegenerative retinal diseases.

At GenSight, he spearheaded financing strategies from their Series B funding to their IPO, along with managing several follow-on transactions and structured finance opportunities. Before his role at GenSight, Thomas was Vice President of Finance at DBV Technologies, overseeing corporate finances and contributing to public offerings and private placements. His career commenced in audit at Ernst & Young in Paris, offering him a strong financial foundation.

Transition to OSE Immunotherapeutics

Thomas takes over from Anne-Laure Autret-Cornet, ushering in a new era of financial leadership within OSE Immunotherapeutics. His expertise arrives at a crucial moment, as the company aims to advance its late-stage assets and leverage its innovative research platform, which is fundamental for its growth strategy.

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, expressed enthusiasm regarding Thomas's arrival, stating:

“As Thomas joins us, his profound experience in biotech capital markets and financial planning equips us with the leadership needed to drive our innovation forward. His strategic vision aligns perfectly with our goals of developing late-stage assets and enhancing our operational focus.”

Vision for the Future

Expressing his excitement, Thomas Gidoin remarked:

“Joining OSE Immunotherapeutics at this pivotal moment is truly exhilarating. With two late-stage assets focused on oncology and inflammation, combined with our innovative research platform, I see tremendous opportunities to create significant long-term value for the company and its stakeholders.”

Company Overview

OSE Immunotherapeutics is a pioneering biotech firm dedicated to developing first-in-class products in immuno-oncology and immuno-inflammation. The company strives to address today's unmet medical needs through collaborations with leading academic institutions and biopharmaceutical companies, aiming to bring transformative medicines to market for patients with serious medical conditions. With strong foundations in Nantes and Paris, OSE Immunotherapeutics is publicly traded on Euronext.

Frequently Asked Questions

Who is the new Chief Financial Officer of OSE Immunotherapeutics?

Thomas Gidoin has been appointed as the new Chief Financial Officer.

What previous experience does Thomas Gidoin have?

Thomas brings over 15 years of experience, including leadership roles at Advesya and GenSight Biologics.

What does OSE Immunotherapeutics focus on?

The company focuses on developing first-in-class assets in immuno-oncology and immuno-inflammation.

Where is OSE Immunotherapeutics based?

OSE Immunotherapeutics operates between Nantes and Paris and is listed on Euronext.

How does Thomas Gidoin plan to contribute to OSE Immunotherapeutics?

Thomas intends to leverage his extensive experience to enhance financial strategies and support the company’s growth and innovation initiatives.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.